Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
Status:
Terminated
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
The effect of nivolumab on symptomatic brain metastases is currently unknown. This phase 2
clinical trial will be the first to evaluate this intracranial effect in humans, with the aim
to give these patients the possibility to be treated with anti-PD-1. Besides the objective
response rate, long term benefits in this patient category will be evaluated by measuring
survival in terms of progression free survival and overall survival. Furthermore safety and
tolerability of administration of this drug in patients with symptomatic brain metastases
will be studied, as this is the first study for nivolumab in this specific patient category.